Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis

ConclusionEnsuring new medicines are authorized in a timely manner to meet the needs of JIA patients worldwide is critical. Approaches should include: open dialogue between regulatory agencies, pharmaceutical companies and other stakeholders to develop and implement novel study designs; including patient and clinician perspectives to define meaningful trial outcomes; and changing existing study plans.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - July 15, 2019 Category: Rheumatology Authors: Laura E. Schanberg, Athimalaipet V Ramanan, Fabrizio De Benedetti, Timothy Beukelman, Guy S. Eakin, Vincent Del Gaizo, Sarah Ringold, Richard Vesely, Suzanne Schrandt, Thomas Jaki, Androniki Bili, James B. Chung, Stephanie De Bono, Wendy Doug Tags: Full Length Source Type: research